Composto Regulado pela FDA
Este composto é aprovado ou regulamentado pela FDA. A compra sem uma prescrição válida pode violar a lei federal. Verifique todas as exigências legais em sua jurisdição.
Dulaglutide
Trulicity
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.
Mecanismo de Ação
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.
Protocolos de Pesquisa
Para fins de pesquisa apenas. Não é conselhos médicos.
Research protocols use 0.75mg weekly, escalating to 1.5mg weekly after 4 weeks. Maximum studied dose is 4.5mg weekly.
Notas de Pesquisa
Clinical Research Status
Dulaglutide received FDA approval in 2014 for type 2 diabetes and has been studied in the extensive AWARD clinical trial program spanning multiple comparator studies. The REWIND cardiovascular outcomes trial demonstrated a 12% reduction in MACE in a broad population including primary prevention patients. It is not currently approved for weight management as a standalone indication.
Key Published Findings
The AWARD trials showed HbA1c reductions of 0.8-1.6% depending on comparator and population studied. REWIND was notable for enrolling a majority of patients without established cardiovascular disease, demonstrating broader preventive benefit. Weight loss in diabetes trials averaged 1.5-3 kg, modest compared to newer GLP-1 agonists optimized for obesity.
Safety Profile
Gastrointestinal adverse events (nausea, diarrhea, vomiting) are the most common side effects, occurring in 15-25% of patients during titration. The same class-wide MTC boxed warning applies, based on rodent thyroid C-cell tumor findings. Injection site reactions are generally mild, and the pre-filled pen device has high patient satisfaction scores.
Comparison to Related Compounds
Compared to semaglutide, dulaglutide produces less weight loss and slightly less HbA1c reduction but uses a simpler auto-injector device that some patients prefer. Its large molecular size (approximately 63 kDa) prevents oral bioavailability, unlike semaglutide which has an oral formulation. Relative to liraglutide, the weekly dosing of dulaglutide offers significant convenience advantage with comparable efficacy.
Community Observations
Trulicity's pen device is frequently cited as one of the most user-friendly among injectable GLP-1 agonists, requiring no needle handling. Patients transitioning from dulaglutide to semaglutide for greater weight loss often report stronger GI side effects initially. Some endocrinologists continue prescribing dulaglutide for patients who prioritize injection simplicity and have modest weight loss goals.
Meio-Vivo
~5 days
Reconstituição
Pre-filled pen (no reconstitution)
Armazenamento
Liofilizado
Refrigerate 2-8C. Do not freeze.
Reconstituído
Room temperature up to 14 days if needed.
Situação Legal nos EUA
Também Conhecido Como
Última Pesquisa
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Highlighting the safety and potential benefits of GLP-1 receptor agonists in managing type 2 diabetes patients with or at risk for acute pancreatitis.
Perguntas frequentes
O que é Dulaglutide?
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.
Como Dulaglutide funciona?
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.
Qual é o status regulatório de Dulaglutide nos EUA?
FDA-approved (Rx only)
Qual é a meia-vida de Dulaglutide?
~5 days
Por quais outros nomes Dulaglutide é conhecido?
Trulicity
Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.
Leia a declaração completa